(Glyco)-protein drug carriers with an intrinsic therapeutic activity: The concept of dual targeting

Journal of Controlled Release

Volumn 39, Issue 2-3, 1996, Pages 163-172

  Meijer, D K F ^a   Molema, G ^a   Moolenaar, F ^a   De Zeeuw, D ^a   Swart, P J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Anti HIV agent; Antiviral protein; AZT; Drug targeting; Glycoprotein; Hepatic targeting; Lysozyme; Naproxen; Negatively charged albumin; Renal targeting

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; DRUG CARRIER; GLYCOPROTEIN;

BINDING AFFINITY; CONFERENCE PAPER; DRUG RESISTANCE; DRUG TARGETING; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0029945745     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(95)00150-6     Document Type: Conference Paper

References (26)

1. D.K.F. Meijer, R.W. Jansen and G. Molema, Drug targeting systems for antiviral agents: options and limitations, Antiviral Res. 18 (1992) 215-248.
2. G. Molema and D.K.F. Meijer, Targeting of drugs to various blood cell types using (neo)-glycoproteins, antibodies and other protein carriers, Adv. Drug Deliv. Rev. 14 (1994) 25-50.
3. D.K.F. Meijer and P. van der Sluijs, Covalent and noncovalent protein binding of drugs: Implications for hepatic clearance, storage, and cell-specific drug delivery, Pharm. Res. 6 (1989) 105-118.
4. D.K.F. Meijer, G. Molema, R.W. Jansen and F. Moolenaar, Design of cell-specific drug targeting preparations for the liver: where cell biology and medicinal chemistry meet, in: H. Timmerman and V. Claassen (Eds), Trends in Drug Research, Proceedings of the Seventh Noordwijkerhout-Camerino Symposium, Pharmacochemistry Library Vol. 13, Weesp, The Netherlands, 1990, pp. 303-333.
5. D.K.F. Meijer, R.W. Jansen and G. Molema, Disposition of macromolecules in the liver in relation to drug targeting, in: G.N.J. Tytgat and M. Van Blankenstein (Eds), Current Topics in Gastroenterology and Hepatology, Georg Thieme Verlag, Stuttgart, 1990, pp. 374-392.
6. D.K.F. Meijer and K. Ziegler, Mechanisms for the hepatic clearance of oligopeptides and proteins. Implications for rate of elimination, bioavailability and cell-specific drug delivery, in: K.L. Audus and T.J. Raub (Eds), Biological Barriers to Protein Delivery, Plenum Press, New York, 1993, pp. 339-407.
7. D.K.F. Meijer and G.M.M. Groothuis, Hepatic transport of drugs and proteins, in: N. McIntyre, J.P. Benhamou, J. Bircher, M. Rizzetto and J. Rodes (Eds), Oxford Textbook of Clinical Hepatology, University Press, Oxford, 1991, pp. 40-78.
8. E.J.F. Franssen, F. Moolenaar, D. de Zeeuw and D.K.F. Meijer, Drug targeting to the kidney with low molecular weight proteins, Adv. Drug Deliv. Rev. 14 (1994) 67-88.
9. E.J.F. Franssen, J. Koiter, C.A.M. Kuipers, A.P. Bruins, F. Moolenaar, D. de Zeeuw, W.H. Kruizinga, R.M. Kellogg and D.K.F. Meijer, Low molecular weight proteins as carriers for renal drug targeting. Preparation of drug-protein conjugates, spacer derivatives of model drugs and their catabolism in renal cortex homogenates and lysosomal lysates, J. Med. Chem. 35 (1992) 1246-1259.
10. E.J.F. Franssen, R.G.M. van Amsterdam, J. Visser, F. Moolenaar, D. de Zeeuw and D.K.F. Meijer, Low molecular weight proteins as carriers for renal drug targeting: naproxen-lysozyme, Pharm. Res. 8 (1991) 1223-1230.
11. E.J.F. Franssen, F. Moolenaar, D. de Zeeuw and D.K.F. Meijer, Low molecular weight proteins as carriers for renal drug targeting: naproxen coupled to lysozyme via the spacer L-lactic acid, Pharm. Res. 10 (1993) 963-969.
12. E.J.F. Franssen, F. Moolenaar, D. de Zeeuw and D.K.F. Meijer, Renal specific delivery of sulfamethoxazole in the rat by coupling to the low molecular weight protein lysozyme via an acid-sensitive linker, Int. J. Pharm. 80 (1992) R15-R19.
13. P. van der Sluijs and D.K.F. Meijer, Limitations in the specificity of targeting asialoglycoprotein drug conjugates to hepatocytes, in: G.Y. Wu and C.H. Wu (Eds), Liver Diseases. Targeted Diagnosis and Therapy using Specific Receptors and Ligands, Marcel Dekker, New York, Chapter 11, 1991, pp. 235-254.
14. R.W. Jansen, G. Molema, T.L. Ching, R. Oosting, G. Harms, F. Moolenaar, M.J. Hardonk and D.K.F. Meijer, Hepatic endocytosis of various types of mannose-terminated albumins. What is important, sugar recognition, net charge, or the combination of these features, J. Biol. Chem. 266 (1991) 3343-3348.
15. R.W. Jansen, G. Molema, G. Harms, J.K. Kruijt, T.J.C. Van Berkel, M.J. Hardonk and D.K.F. Meijer, Formaldehyde treated albumin contains monomeric and polymeric forms that are differently cleared by endothelial and Kupffer cells of the liver: evidence for scavenger receptor heterogeneity, Biochem. Biophys. Res. Commun. 180 (1991) 3343-3348.
16. P. van der Sluijs, H.P. Bootsma, B. Postema, F. Moolenaar and D.K.F. Meijer, Drug targeting to the liver with lactosylated albumins: Does the glycoprotein target the drug or is the drug targeting the glycoprotein? Hepatology 6 (1986) 723-728.
17. E.J.F. Franssen, R.W. Jansen, M. Vaalburg and D.K.F. Meijer, Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules, Biochem. Pharmacol. 45 (1993) 1215-1226.
18. R.W. Jansen, J.K. Kruijt, T.J.C. Van Berkel and D.K.F. Meijer, Coupling of the antiviral drug ara-AMP to lactosaminated albumin leads to specific uptake in rat and human hepatocytes, Hepatology 18 (1993) 146-152.
19. G. Molema, R.W. Jansen, R. Pauwels, E. de Clercq and D.K.F. Meijer, Targeting of antiviral drugs to T4-lymphocytes. Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro, Biochem. Pharmacol. 39 (1990) 2603-2610.
20. G. Molema, R.W. Jansen, J. Visser, P. Herdewijn, F. Moolenaar and D.K.F. Meijer, Neoglycoproteins as carriers for antiviral drugs: synthesis and analysis of protein-drug conjugates, J. Med. Chem. 43 (1991) 1137-1141.
21. R.W. Jansen, D. Schols, R. Pauwels, E. de Clercq and D.K.F. Meijer, Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity, Mol. Pharmacol. 44 (1993) 1003-1007.
22. R.W. Jansen, G. Molema, R. Pauwels, D. Schols, E. de Clercq and D.K.F. Meijer, Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins, Mol. Pharmacol. 39 (1991) 818-823.
23. R.W. Jansen, P. Olinga, G. Harms and D.K.F. Meijer, Pharmacokinetic analysis and cellular distribution of anti-HIV compound succinylated human serum albumin (suc-HSA) in vivo and in isolated perfused rat liver, Pharm. Res. 10 (1993) 1611-1614.
24. G. Molema, R.W. Jansen, J. Visser and D.K.F. Meijer, Simultaneous analysis of azidothymidine and its mono-, diand triphosphate derivatives in biological fluids, tissue and cultured cells by a rapid high-performance liquid chromatographic method, J. Chromatogr. 579 (1992) 107-114.
25. D.K.F. Meijer, K. Keulemans and G.J. Mulder, Isolated perfused rat liver technique, Methods Enzymol. 77 (1981) 81-93.
26. M. Witvrouw, J. Desmijter and E. De Clercq, Antiviral portrait series: 4. Polysulfates as inhibitors of HIV and other enveloped viruses, Antiviral Chem. Chemother. 5 (1994) 345-359.